What will be D/D of CIDP
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Now I have enough from the textbooks. Let me compile the comprehensive differential diagnosis of CIDP.
Differential Diagnosis of CIDP
CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is defined by progressive proximal and distal weakness with sensory loss evolving over >8 weeks. Up to 50% of patients may be misdiagnosed - most often due to misinterpretation of nerve conduction study data. The D/D must be considered systematically.
1. Other Acquired Demyelinating Neuropathies
| Condition | Key Distinguishing Features |
|---|---|
| GBS (AIDP) | Acute onset, maximal deficit within 4 weeks; monophasic; does not relapse |
| Acute-onset CIDP | Looks like GBS initially, but deteriorates >9 weeks after onset OR relapses ≥3 times |
| Multifocal Motor Neuropathy (MMN) | Pure motor, asymmetric, distal predominance; anti-GM1 antibodies; NO sensory loss |
| MADSAM (Lewis-Sumner Syndrome) | A variant of CIDP itself - asymmetric, discrete nerve involvement |
| DADS neuropathy | Distal acquired demyelinating symmetric neuropathy; associated with IgM-kappa MGUS |
| Anti-MAG neuropathy | IgM monoclonal gammopathy + antibodies to myelin-associated glycoprotein; predominantly sensory/sensory ataxia |
(Source: Harrison's Principles of Internal Medicine, 22E; Bradley and Daroff's Neurology)
2. Hereditary Demyelinating Neuropathies
| Condition | Key Distinguishing Features |
|---|---|
| CMT1 (Charcot-Marie-Tooth type 1) | Slow NCS from birth, family history, pes cavus, hammer toes, PMP22 duplication; symmetric uniform slowing (vs. non-uniform in CIDP) |
| CMT-X (CMTX1) | X-linked; Cx32 mutation; males more severely affected |
| Hereditary Neuropathy with Pressure Palsies (HNPP) | PMP22 deletion; episodic nerve palsies at compression sites |
| Dejerine-Sottas disease (CMT3) | Severe early-onset; very low NCVs |
| Refsum disease | Elevated serum phytanic acid; retinitis pigmentosa, deafness, ichthyosis |
(Source: Goldman-Cecil Medicine; Adams and Victor's Neurology; Harrison's 22E)
3. Paraproteinemic Neuropathies
| Condition | Key Distinguishing Features |
|---|---|
| MGUS-associated neuropathy | Serum protein electrophoresis shows M-protein; IgM > IgG/IgA |
| POEMS syndrome | Polyneuropathy + Organomegaly + Endocrinopathy + M-protein + Skin changes; osteosclerotic myeloma |
| Multiple myeloma neuropathy | Axonal or demyelinating; Bence Jones protein; lytic lesions |
| Waldenström macroglobulinemia | IgM paraprotein; hyperviscosity |
| Primary amyloidosis (AL) | Painful small fiber neuropathy predominant; Congo red positive deposits |
4. Metabolic and Systemic Diseases
| Condition | Key Distinguishing Features |
|---|---|
| Diabetic neuropathy | Symmetrical distal, predominantly axonal; diabetes history |
| Hypothyroidism | Slowed reflexes, predominantly axonal sensory neuropathy |
| Vasculitis neuropathy | Mononeuritis multiplex pattern; asymmetric; axonal on NCS |
| SLE / connective tissue disease | Systemic features; ANA/anti-dsDNA positive |
| Sarcoidosis | Cranial nerve involvement; systemic sarcoid features; CSF pleocytosis |
| Chronic hepatitis B/C | Serology positive |
| HIV infection | CD4 count, HIV serology; CSF pleocytosis may be present |
5. Infectious / Inflammatory Causes
| Condition | Key Distinguishing Features |
|---|---|
| Lyme neuroborreliosis | Exposure history; radiculitis pattern; Borrelia serology |
| Leprosy | Endemic area; skin patches; thickened superficial nerves |
| CMV polyradiculopathy | Immunocompromised host; CSF pleocytosis |
| Neurosarcoidosis | Cranial neuropathies; lung/skin involvement |
| Chronic lymphoma/leukemia | CSF cytology; nerve biopsy - lymphomatous infiltration |
6. Paraneoplastic Neuropathy
- Usually sensory neuronopathy (Sjogren's, anti-Hu antibody) rather than motor
- Associated with small cell lung cancer, thymoma, ovarian teratoma
- Anti-Hu, anti-CV2 antibodies
7. Other Conditions to Exclude
| Condition | Key Points |
|---|---|
| Spinal cord/cauda equina lesion | Myelopathy; sensory level; bladder involvement |
| Motor neuron disease (ALS) | No sensory loss; UMN + LMN signs; NCS normal early |
| Multifocal Motor Neuropathy | Purely motor; anti-GM1 IgM antibodies; responds to IVIG but NOT steroids |
| Chronic inflammatory sensory polyradiculopathy (CISP) | Pure sensory ataxia variant; demyelination at sensory roots |
Key Investigations to Guide D/D
- NCS/EMG: Demyelinating features (conduction block, temporal dispersion, prolonged latencies) - hallmark of CIDP; uniform slowing suggests hereditary
- CSF: Elevated protein, acellular (cytoalbuminous dissociation); pleocytosis suggests HIV, lymphoma, sarcoidosis
- Serum protein electrophoresis + immunofixation: For paraprotein / MGUS
- Genetic testing: If clinical suspicion of CMT (young age, family history, symmetric uniform NCS slowing)
- Anti-GM1 antibodies: For MMN
- Anti-MAG antibodies: For IgM MGUS neuropathy
- ANA, ANCA, HBsAg, HCV, HIV: For systemic causes
- MRI: Nerve root/plexus enhancement or enlargement supports CIDP
(Source: Harrison's Principles of Internal Medicine 22E, p. 3659-3661; Goldman-Cecil Medicine)
Bottom line: The most important conditions to differentiate from CIDP are GBS (acute vs. chronic timeline), MMN (pure motor, anti-GM1+), CMT1 (hereditary, uniform NCS slowing, lifelong history), and paraproteinemic neuropathies (serum electrophoresis mandatory in all CIDP suspects). Overdiagnosis is common - always verify NCS criteria are truly met.
This is a shared conversation. Sign in to Orris to start your own chat.